Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group.
OBJECTIVE
In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1.


METHODS
A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System.


RESULTS
Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V.


CONCLUSIONS
The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.
Oue
Takaharu
T
Division of Pediatric Surgery, Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. ooue@pedsurg.med.osaka-u.ac.jp
Fukuzawa
Masahiro
M
Okita
Hajime
H
Mugishima
Hideo
H
Horie
Hiroshi
H
Hata
Jun-ichi
J
Saito
Masahiro
M
Nozaki
Miwako
M
Chin
Motoaki
M
Nakadate
Hisaya
H
Hinotsu
Shiro
S
Koshinaga
Tsugumichi
T
Kaneko
Yasuhiko
Y
Kitano
Yoshihiro
Y
Tanaka
Yukichi
Y
D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D018335:Rhabdoid Tumor / Q000401:mortality / Q000628:therapy*; D018227:Sarcoma, Clear Cell / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D009396:Wilms Tumor / Q000401:mortality / Q000628:therapy*
J Clin Oncol. 2005 Dec 20;23(36):9138-45
16172460
Am J Surg Pathol. 1989 Jun;13(6):439-58
2543225
Lifetime Data Anal. 2007 Dec;13(4):463-70
18027087
Cancer. 1976 Aug;38(2):633-46
184912
Ann Oncol. 2001 Mar;12(3):311-9
11332141
Med Pediatr Oncol. 1994;22(4):221-7
8107651
Mol Carcinog. 2008 Sep;47(9):660-6
18286482
J Clin Oncol. 2005 Oct 10;23(29):7312-21
16129848
Lancet. 2004 Oct 2-8;364(9441):1229-35
15464183
Hum Pathol. 1981 Jul;12(7):646-57
7275104
Cancer. 1978 May;41(5):1937-48
206343
Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60
16216623
J Clin Oncol. 1994 Oct;12(10):2132-7
7931484
Ann Surg. 1999 Feb;229(2):292-7
10024113
Eur J Cancer. 2006 Oct;42(15):2554-62
16904312
Genes Chromosomes Cancer. 2006 Jun;45(6):592-601
16518847
J Clin Oncol. 2001 Sep 1;19(17):3719-24
11533093
J Pediatr Surg. 1977 Oct;12(5):631-8
72143
J Urol. 1987 Oct;138(4 Pt 2):968-73
2821293
Cancer. 1984 Dec 15;54(12):2978-87
6093989
J Urol. 1991 Aug;146(2 ( Pt 2)):514-8
1650403
Genes Chromosomes Cancer. 2008 Aug;47(8):712-27
18464243